Aldeyra Therapeutics’ (ALDX) “Neutral” Rating Reiterated at HC Wainwright

Aldeyra Therapeutics (NASDAQ:ALDX)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $2.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 53.26% from the stock’s current price.

A number of other brokerages have also commented on ALDX. Wall Street Zen lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. BTIG Research restated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday. Finally, Weiss Ratings lowered Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, September 14th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Aldeyra Therapeutics currently has an average rating of “Hold” and a consensus target price of $5.50.

Aldeyra Therapeutics Stock Down 1.1%

ALDX stock traded down $0.02 during midday trading on Wednesday, reaching $1.31. The stock had a trading volume of 792,038 shares, compared to its average volume of 1,753,725. The business has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $1.73. The firm has a market cap of $78.73 million, a price-to-earnings ratio of -3.35 and a beta of 1.20. Aldeyra Therapeutics has a twelve month low of $1.07 and a twelve month high of $5.93.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). On average, equities analysts predict that Aldeyra Therapeutics will post -0.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aldeyra Therapeutics

Institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at about $2,678,000. 683 Capital Management LLC lifted its holdings in shares of Aldeyra Therapeutics by 86.6% during the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after purchasing an additional 710,000 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at about $1,007,000. Renaissance Technologies LLC lifted its holdings in shares of Aldeyra Therapeutics by 146.6% during the 1st quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock valued at $1,459,000 after purchasing an additional 513,187 shares in the last quarter. Finally, Hikari Power Ltd bought a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at about $43,000. Institutional investors own 59.71% of the company’s stock.

Key Stories Impacting Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Aldeyra announced its intent to submit a formal dispute resolution request (FDRR) regarding the FDA’s third complete response letter for reproxalap. The move could provide another opportunity to address the agency’s concerns and seek reconsideration of the dry-eye treatment. Aldeyra Announces Intent to Submit Formal Dispute Resolution Request
• Positive Sentiment: Investors initially responded favorably to the dispute-resolution strategy, with reports describing a rally in ALDX shares as the company pushed back against the FDA decision. Aldeyra Fights Back Against FDA Rejection
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating, indicating that the analyst sees meaningful upside if Aldeyra can advance reproxalap through the regulatory process.
• Neutral Sentiment: HC Wainwright maintained a “neutral” rating but set a $2.00 price target, implying substantial upside from recently quoted levels while signaling that significant regulatory and execution risks remain.
• Negative Sentiment: The FDRR follows a third FDA complete response letter, underscoring repeated regulatory setbacks. The dispute process does not guarantee approval and may prolong development costs and timelines for the company.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory mediators that can contribute to tissue damage and disease progression.

Aldeyra’s lead investigational product is reproxalap, a small-molecule RASP inhibitor being developed for ocular conditions, including dry eye disease and allergic conjunctivitis. The company has also developed ADX-2191, an investigational intravitreal formulation of methotrexate intended for the treatment of certain rare retinal diseases, including proliferative vitreoretinopathy and retinitis pigmentosa.

Founded in 2008 and headquartered in Lexington, Massachusetts, Aldeyra conducts its research and clinical development activities primarily in the United States.